Corvus Pharmaceuticals, Inc. (CRVS) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
CRVS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CRVS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CRVS earnings history in CSV or JSON format
Free sign-in required to download data
Corvus Pharmaceuticals, Inc. (CRVS) Earnings Overview
As of May 8, 2026, Corvus Pharmaceuticals, Inc. (CRVS) reported trailing twelve-month net income of -$44M, reflecting +48.0% year-over-year growth. The company earned $-0.49 per diluted share over the past four quarters.
Looking at the long-term picture, CRVS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$176,000 in fiscal 2014.
Corvus Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), RCUS (-$369M net income, -142.9% margin), TPVG (-$12M net income, 50.6% margin), CRVS has comparable earnings metrics. Compare CRVS vs IMVT →
CRVS Earnings vs Peers
Earnings metrics vs comparable public companies
CRVS Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$15M | +75.5% | -$43M | $-0.53 | - | - |
| 2024 | -$62M | -130.5% | -$28M | $-1.02 | - | - |
| 2023 | -$27M | +34.6% | -$23M | $-0.56 | - | - |
| 2022 | -$41M | +4.5% | -$33M | $-0.89 | - | - |
| 2021 | -$43M | -621.3% | -$39M | $-1.03 | - | - |
| 2020 | -$6M | +87.2% | -$44M | $-0.20 | - | - |
| 2019 | -$47M | +0.6% | -$49M | $-1.49 | - | - |
| 2018 | -$47M | +15.7% | -$49M | $-1.71 | - | - |
| 2017 | -$56M | -53.0% | -$57M | $-2.72 | - | - |
| 2016 | -$36M | -16.1% | -$37M | $-2.36 | - | - |
See CRVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRVS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRVS — Frequently Asked Questions
Quick answers to the most common questions about buying CRVS stock.
Is CRVS growing earnings?
CRVS EPS is $-0.49, with earnings growth accelerating to +48.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-44M.
What are CRVS's profit margins?
Corvus Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CRVS's earnings?
CRVS earnings data spans 2014-2025. The accelerating earnings trend is +48.0% YoY. Historical data enables comparison across business cycles.